Amentum Holdings just beat Q2 estimates on both the top and bottom line. The stock barely moved. That gap between a decent print and an unmoved price is the central tension heading into the week.
Short sellers stepped up their activity noticeably this week. Short interest climbed 16% over the past seven days to 5.8% of free float — the sharpest weekly build in at least six weeks. From early April through late April, the position held fairly steady in the 11–12 million share range. Then, starting Monday May 11, it jumped by roughly 2.3 million shares in two sessions. The ORTEX short score has risen in tandem, reaching 58.7 — its highest reading in the available history and up from 53.1 a week ago. Borrow costs have actually eased, down 14% on the week to 0.36% annualised, suggesting the new short positions are being established easily and at low friction. Borrow availability remains well within normal range, so there is no mechanical squeeze pressure here. Options tell a similar story of measured caution rather than alarm — the put/call ratio is 0.37, marginally below its 20-day average of 0.39 and a full standard deviation below it, meaning options traders are not rushing for downside protection. The divergence is interesting: equity shorts are building, but options hedgers are relaxed.
The Street reaction to the Q2 print landed swiftly and in one direction — lower price targets. RBC Capital cut its target from $35 to $28 on May 13, maintaining a Sector Perform. Truist Securities, a bull, slashed its target from $42 to $35 while reiterating its Buy. Both cuts arrived post-earnings. The consensus mean now sits at $34.82, implying 43% upside from the $24.31 close — a gap that looks wide but partly reflects the gap-down the stock has endured since its public-market debut. Bears point to the difficult start as a listed company, the impact of last year's record 43-day government shutdown on free cash flow, and uncertainty around when private equity backers Lindsay Goldberg and American Securities — together holding roughly 37% of shares — will trim their stakes. Bulls counter with a large contract backlog, exposure to high-growth areas including nuclear energy and missile defence, and a valuation of 8.5x EV/EBITDA that leaves room for re-rating if contract wins accelerate. The price-to-book has contracted by roughly 12% over the past month, and the PE ratio has slid by 1.4 turns over the same period. RSI14 at 36 suggests the stock is approaching technically oversold territory without yet triggering a recovery signal.
Insiders added a familiar wrinkle on May 6, though context matters here. The CEO, CFO, COO, and CTO all received equity awards and immediately sold a portion to cover tax withholding — a routine vest-and-sell pattern. The CEO sold roughly 8,200 shares at $24.89, the CFO around 4,100 shares. Net 90-day insider activity is modestly positive at roughly 24,000 shares, but the gross sales reflect compensation mechanics rather than conviction selling. On the institutional side, Invesco added more than 2.4 million shares in the most recent reporting period, nudging its stake toward 9.1% of the float. Vanguard and PRIMECAP also added incremental positions. The buyer base is not abandoning the name.
The earnings beat — adjusted EPS of $0.60 against a $0.57 estimate, revenue of $3.48 billion against $3.47 billion — was real but narrow. Full-year guidance was affirmed, with FY2026 adjusted EPS framed at $2.25–$2.45 versus the $2.41 consensus and sales at $13.95–$14.30 billion against a $14.12 billion estimate. Guidance affirmation in the middle of a DOGE-era government spending debate is not trivial, but the stock's near-flat post-earnings reaction (-0.9% the following day) suggests investors wanted more than a hold. Peers provide additional colour on the week: LDOS and BAH — the closest defence-services comparables — both fell modestly on the week, around 6% and 1% respectively, while CACI managed a 1% gain. AMTM's near-flat weekly print looks better in that context, though the short-interest rebuild suggests not everyone is reassured.
What to watch next is the pace at which short interest either consolidates or continues growing — the May 11–12 jump happened on top of a Q2 beat, which makes the renewed build notable — alongside any commentary from the two large PE holders about a potential secondary or lock-up modification.
See the live data behind this article on ORTEX.
Open AMTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
